For instance, one clinical trial tested first‐line anti‐PD1 in NSCLC and failed to prolong progression‐free survival in patients with >5% PD‐L1 expression.[105] Therefore, holistic assessment of the TME, beyond neoantigen appearance and mutational burden, is required for different types of cancer. This evidence concerns the gene CD274 and cancer.